Indian pharma is exempt from Trump’s 2025 tariffs — for now. Specialty & biosimilar firms hold strong, but generics-heavy players face margin, regulatory risk.
We did a similar deep-dive. Good to see we are aligned on the big picture risks!
https://nordicedge.substack.com/p/patents-pills-and-protectionism-the
We did a similar deep-dive. Good to see we are aligned on the big picture risks!
https://nordicedge.substack.com/p/patents-pills-and-protectionism-the